Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides

Serena Rupoli,Lucia Canafoglia,Gaia Goteri,Pietro Leoni,Giuliano Brandozzi,Irene Federici,Giorgia Micucci,Federica Giantomassi,G. Mozzicafreddo,Renato Alterini,Giorgio Filosa,G. Ricotti,Marco Simonacci,Anna Rita Scortechini,Antonio Zizzi,Nicola Pimpinelli

Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides

2016

Serena Rupoli
Lucia Canafoglia
Gaia Goteri
Pietro Leoni
Giuliano Brandozzi
Irene Federici
Giorgia Micucci
Federica Giantomassi
G. Mozzicafreddo
Renato Alterini
Giorgio Filosa
G. Ricotti
Marco Simonacci
Anna Rita Scortechini
Antonio Zizzi
Nicola Pimpinelli

Introduction Bexarotene is a synthetic retinoid effective in early and advanced stages of mycosis fungoides (MF)/Sezary Syndrome (SS) both in monotherapy and combination schemes.

Keywords:

Prospective cohort study
Anticarcinogenic Agents
Refractory
Medicine
Dermatology
Retinoid
Mycosis fungoides
Bexarotene
synthetic retinoid
advanced stage
low dose

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations